Hermetica Superfood Encyclopedia
The Short Answer
5-MTHF is the biologically active, reduced form of folate that donates methyl groups via methionine synthase (EC 2.1.1.13) to remethylate homocysteine to methionine, driving S-adenosylmethionine (SAM) synthesis for DNA methylation, neurotransmitter production, and one-carbon metabolism. Unlike synthetic folic acid, it bypasses the rate-limiting MTHFR enzyme conversion step, making it effective in the estimated 40–60% of the population carrying MTHFR C677T or A1298C polymorphisms that impair folic acid bioactivation.
CategoryVitamin
GroupMineral
Evidence LevelPreliminary
Primary Keyword5-MTHF benefits
5-Methyltetrahydrofolate — botanical close-up
Health Benefits
**MTHFR Polymorphism Bypass**
5-MTHF enters the folate cycle downstream of the MTHFR enzyme, meaning individuals with C677T or A1298C variants who cannot efficiently convert folic acid still achieve effective tissue folate repletion without the enzymatic bottleneck.
**Homocysteine Reduction**
As the direct methyl donor for methionine synthase, 5-MTHF lowers elevated plasma homocysteine, a cardiovascular risk factor; supplementation consistently reduces homocysteine by 15–25% in controlled trials when combined with B6 and B12.
**Neural Tube Defect Prevention**
Adequate periconceptional 5-MTHF status reduces the risk of neural tube defects (NTDs) such as spina bifida and anencephaly by up to 70%, consistent with decades of epidemiological and interventional data underpinning global public health recommendations.
**DNA Synthesis and Repair Support**
5-MTHF provides one-carbon units essential for de novo thymidylate and purine synthesis via thymidylate synthase and AICAR transformylase, ensuring genomic integrity during rapid cell division and reducing uracil misincorporation into DNA.
**SAM-Dependent Methylation and Neurotransmitter Synthesis**: By driving methionine and SAM production, 5-MTHF supports methylation of catecholamines (dopamine, norepinephrine), serotonin precursors, and myelin basic protein, with clinical relevance to mood regulation and depression, particularly in patients with low folate status.
**Anemia Prevention**
5-MTHF corrects megaloblastic anemia caused by folate deficiency by restoring thymidylate synthesis and enabling proper red blood cell maturation; unlike folic acid, it does not mask vitamin B12 deficiency-related neurological symptoms in the same way when correctly dosed.
**Cardiovascular Risk Reduction**
Through homocysteine lowering and maintenance of endothelial nitric oxide synthase (eNOS) coupling, adequate 5-MTHF status is associated with improved endothelial function and reduced markers of oxidative vascular stress in observational and intervention studies.
Origin & History
Natural habitat
5-MTHF is not derived from a single geographic or botanical source but is the predominant circulating form of folate (vitamin B9) found naturally in leafy green vegetables, legumes, liver, and fermented foods. Industrially, it is synthesized via continuous-flow chemical processes from folic acid, involving sequential hydrogenation and methylenation steps, yielding purities above 99% as the calcium salt (calcium L-5-methyltetrahydrofolate). It also accumulates naturally in fermented green tea kombucha through microbial biosynthesis by strains including Microbacterium species, reaching peak concentrations of approximately 55 µg/mL after 21 days of fermentation.
“Folate as a nutrient was first isolated from spinach by Lucy Wills and colleagues in the 1930s–1940s while investigating nutritional macrocytic anemia in pregnant women in India, with the active vitamin later identified as folic acid in 1941 by Mitchell and colleagues. The specific biologically active form, 5-methyltetrahydrofolate, was characterized in the 1960s as the predominant circulating folate species in human plasma and cerebrospinal fluid, distinguished from the synthetic folic acid form through advanced chromatographic and isotopic techniques. Unlike many botanical ingredients with centuries of traditional use, 5-MTHF has no historical ethnomedicinal record as an isolated compound; its clinical relevance emerged entirely from 20th-century nutritional biochemistry, particularly with the discovery of the MTHFR gene and its common polymorphisms in the 1990s, which transformed understanding of why synthetic folic acid supplementation is inadequate for a large segment of the population. The global public health context of folic acid fortification programs beginning in the 1990s (USA, Canada, and over 80 countries) laid the groundwork for recognition that 5-MTHF supplementation represents a more physiologically appropriate strategy for populations with impaired folate bioactivation.”Traditional Medicine
Scientific Research
The evidence base for 5-MTHF is substantial for specific endpoints such as neural tube defect prevention and homocysteine reduction, supported by multiple randomized controlled trials and systematic reviews that form the basis of global dietary recommendations, though direct head-to-head comparisons of 5-MTHF versus folic acid in large independent RCTs are less numerous than the broader folate literature. Comparative bioavailability studies confirm that calcium L-5-methyltetrahydrofolate raises red blood cell and plasma folate levels at least as effectively as equimolar folic acid, with advantages in MTHFR-variant carriers documented in smaller controlled trials of 50–200 participants. For depression and neuropsychiatric indications, pilot RCTs and open-label studies of 15 mg/day adjunctive 5-MTHF report significant reductions in depressive symptom scores, though sample sizes remain small (n=20–100) and replication in large multicenter trials is limited. A cohort study examining cerebrospinal fluid 5-MTHF in children with autism spectrum disorder found no significant correlation between CSF 5-MTHF levels and ASD symptom severity, adaptive behavior, or cognitive outcomes (r=0.38, p=0.04), and highlighted high natural variability in pediatric CSF folate, indicating that the clinical utility of CSF 5-MTHF as a biomarker in ASD requires further investigation.
Preparation & Dosage
Traditional preparation
**Calcium L-5-methyltetrahydrofolate (oral supplement, tablet/capsule)**
400–800 µg/day for general folate supplementation and neural tube defect prevention; up to 1000 µg/day for MTHFR variant carriers or elevated homocysteine.
**High-dose 5-MTHF (prescription or clinical formulation)**
5–15 mg/day used adjunctively in treatment-resistant depression protocols under medical supervision; this dose range is approximately 15–37 times the standard RDA equivalent
7..
**Fermented food sources (kombucha)**
Green tea kombucha fermented for 7–21 days naturally accumulates 5-MTHF at concentrations of 39–55 µg/mL as measured by HPLC-DAD; not a standardized supplemental source but demonstrates natural bioavailability from fermented matrices.
**Prenatal supplements**
Typically formulated at 400–1000 µg per serving as calcium L-5-MTHF, replacing or complementing folic acid; ideally initiated at least one month before conception and continued through the first trimester.
**Industrial synthesis form**
Produced via continuous-flow hydrogenation of folic acid (53.54% yield, 71.4-minute residence time) as calcium salt with >99% purity for pharmaceutical-grade supplementation.
**Timing**
No strict timing requirement demonstrated; consistent daily intake preferable; may be taken with food to minimize any gastrointestinal sensitivity at higher doses.
**Standardization**
Pharmaceutical-grade calcium L-5-MTHF is standardized to >99% purity; dietary supplements should declare content as L-methylfolate equivalents in micrograms of dietary folate equivalents (DFE).
Nutritional Profile
5-MTHF is a micronutrient compound rather than a macronutrient source; it provides no caloric, protein, fat, or carbohydrate content. As a reduced pteroylmonoglutamate, its molecular weight is 459.46 g/mol (calcium salt: 497.5 g/mol), and it is water-soluble with pH-dependent stability (optimal stability at pH 4–7; degrades under alkaline conditions, UV light, and oxidative environments). In dietary sources, leafy greens such as spinach provide 100–200 µg DFE per 100g primarily as polyglutamate folates requiring intestinal hydrolysis, whereas supplemental calcium L-5-MTHF is the monoglutamate form with direct intestinal absorption via the proton-coupled folate transporter (PCFT/SLC46A1) and reduced folate carrier (RFC/SLC19A1). Bioavailability of supplemental 5-MTHF is approximately 85–100% relative to folic acid under standard conditions, and critically is not subject to saturation of DHFR at high intakes (a limitation of folic acid that leads to unmetabolized folic acid in plasma). No associated phytochemicals, cofactors, or secondary metabolites are intrinsic to the isolated compound; synergistic co-factors in metabolism include vitamin B12, vitamin B6, riboflavin (FAD as MTHFR cofactor), and zinc.
How It Works
Mechanism of Action
5-MTHF functions as the obligate methyl donor for methionine synthase (EC 2.1.1.13), transferring its N5-methyl group to cobalamin (vitamin B12)-bound cob(I)alamin, which then remethylates homocysteine to methionine; this regenerates tetrahydrofolate (THF) for continued one-carbon cycling and produces methionine for S-adenosylmethionine (SAM) biosynthesis via methionine adenosyltransferase. SAM subsequently serves as the universal methyl donor for over 200 methyltransferase reactions governing DNA CpG methylation (via DNMT1, DNMT3a/b), histone methylation, phosphatidylcholine synthesis, and neurotransmitter N-methylation, fundamentally regulating gene expression and cellular differentiation. Critically, 5-MTHF does not require activation by dihydrofolate reductase (DHFR) or methylenetetrahydrofolate reductase (MTHFR), the enzyme encoded by the polymorphic MTHFR gene; this allows direct cellular utilization regardless of MTHFR enzymatic activity, unlike folic acid which must traverse both reduction steps. Additionally, 5-MTHF maintains eNOS in its coupled, nitric-oxide-producing state by recycling the eNOS cofactor tetrahydrobiopterin (BH4) indirectly through suppression of oxidative stress associated with hyperhomocysteinemia, thereby supporting vascular endothelial function.
Clinical Evidence
The most robustly evidenced clinical application of 5-MTHF is periconceptional supplementation for neural tube defect prevention, where folate intervention trials have demonstrated up to 70% risk reduction, underpinning recommendations of 400–800 µg daily for women of childbearing age. Homocysteine-lowering trials confirm that 5-MTHF at doses of 400–1000 µg/day reduces plasma homocysteine by approximately 15–25% in hyperhomocysteinemic individuals, particularly when co-administered with vitamins B6 and B12, with cardiovascular surrogate endpoint improvements observed but definitive mortality benefits not yet established from 5-MTHF-specific trials. For depression, small RCTs and case series using 5-MTHF at 7.5–15 mg/day as adjunctive therapy to antidepressants report clinically meaningful reductions in Hamilton Depression Rating Scale scores, especially in patients with low baseline folate or MTHFR variants, but large Phase III trials are absent. The ASD CSF study adds context that elevated or supplemented 5-MTHF in cerebrospinal fluid does not correlate linearly with neurodevelopmental clinical markers, reflecting the complexity of folate metabolism in the central nervous system and the need for further controlled trials to define therapeutic windows in neurological indications.
Safety & Interactions
At standard supplemental doses of 400–1000 µg/day, 5-MTHF is considered safe with a well-established tolerability profile; adverse effects are rare and may include mild gastrointestinal symptoms (nausea, bloating) at higher doses, and isolated reports of sleep disturbances, irritability, or anxiety at doses above 5 mg/day in sensitive individuals, potentially due to rapid increases in methylation flux. A critical drug interaction exists with methotrexate, a DHFR inhibitor and antifolate chemotherapy/immunosuppressant agent; 5-MTHF can reduce methotrexate toxicity but may also attenuate its therapeutic efficacy in oncology settings, and co-administration should only occur under specialist guidance. 5-MTHF may also interact with anticonvulsants including phenytoin, carbamazepine, and valproate, which reduce folate absorption and increase degradation; conversely, high-dose folate may alter serum levels of these drugs and should be monitored. In pregnancy, 5-MTHF at recommended doses (400–800 µg/day) is safe and preferred over folic acid for women with MTHFR variants; doses above 1 mg/day should be medically supervised, and unlike folic acid, 5-MTHF does not mask vitamin B12 deficiency hematological signs at typical supplemental doses, though neurological masking at very high doses remains a theoretical concern requiring further study.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
L-5-methyltetrahydrofolateCalcium L-5-methyltetrahydrofolateL-methylfolateLevomefolic acid5-MTHFMetafolinQuatrefolic
Frequently Asked Questions
What is the difference between 5-MTHF and folic acid?
Folic acid is a synthetic, oxidized form of vitamin B9 that must be converted to the active 5-MTHF through two enzymatic steps involving DHFR and MTHFR before the body can use it, whereas 5-MTHF is already in the biologically active, reduced form ready for direct cellular uptake and use. In individuals carrying MTHFR C677T or A1298C polymorphisms — affecting an estimated 40–60% of the population — MTHFR enzyme activity is reduced by 30–70%, meaning folic acid conversion is impaired and unmetabolized folic acid accumulates in plasma, while 5-MTHF supplementation bypasses this bottleneck entirely.
What dose of 5-MTHF should I take if I have an MTHFR mutation?
For individuals with MTHFR variants, typical supplemental doses of 400–1000 µg/day of calcium L-5-methyltetrahydrofolate are used for general folate repletion, neural tube defect prevention, and mild homocysteine management. Higher doses of 7.5–15 mg/day have been used clinically in treatment-resistant depression under medical supervision, but doses above 1 mg/day should be assessed by a healthcare provider, particularly to rule out underlying vitamin B12 deficiency before initiating high-dose methylfolate.
Can 5-MTHF help with depression?
5-MTHF supports neurotransmitter synthesis by driving S-adenosylmethionine (SAM) production, which is required for the methylation of monoamine precursors including dopamine, serotonin, and norepinephrine; low folate status is associated with reduced antidepressant response and increased depressive symptoms. Small clinical trials using 15 mg/day of 5-MTHF as an adjunct to standard antidepressant therapy have reported meaningful reductions in Hamilton Depression Rating Scale scores, particularly in patients with low baseline folate, MTHFR variants, or treatment-resistant depression, though large Phase III RCTs confirming efficacy are still needed.
Is 5-MTHF safe during pregnancy?
Yes, 5-MTHF at 400–800 µg/day is considered safe in pregnancy and is increasingly recommended over synthetic folic acid, particularly for women with MTHFR polymorphisms who cannot efficiently convert folic acid to the active form needed for neural tube closure during the first 28 days of fetal development. For women known to have MTHFR mutations or a prior NTD-affected pregnancy, healthcare providers may recommend higher doses (up to 5 mg/day) under supervision; 5-MTHF does not carry the same risk of masking B12 deficiency at standard doses as has been raised for high-dose folic acid.
Does 5-MTHF interact with any medications?
The most clinically significant interaction is with methotrexate, an antifolate drug used in cancer treatment and autoimmune conditions; 5-MTHF can reduce methotrexate-related toxicity but may compromise its therapeutic antiproliferative effect, so co-administration requires specialist oversight. Anticonvulsants including phenytoin, carbamazepine, and valproate reduce folate absorption and increase its catabolism, and conversely high folate intake may alter serum anticonvulsant levels; patients on these medications should have folate and drug levels monitored if supplementing with 5-MTHF above standard dietary amounts.
How does 5-MTHF help people with MTHFR gene variants?
5-MTHF bypasses the MTHFR enzyme entirely by entering the folate metabolism pathway downstream of where the enzyme normally works, allowing individuals with C677T or A1298C variants to achieve adequate tissue folate levels without relying on efficient enzyme conversion. This is particularly beneficial for those who cannot efficiently convert standard folic acid into its active form due to these genetic polymorphisms. By circumventing the enzymatic bottleneck, 5-MTHF provides direct metabolic benefit regardless of MTHFR function status.
Can 5-MTHF lower homocysteine levels?
Yes, 5-MTHF acts as the direct methyl donor required by the enzyme methionine synthase to convert homocysteine into methionine, thereby reducing elevated plasma homocysteine concentrations. Elevated homocysteine is associated with cardiovascular and neurological risks, making homocysteine reduction a clinically relevant outcome for 5-MTHF supplementation. Several studies demonstrate that adequate 5-MTHF status correlates with lower homocysteine levels, particularly when combined with adequate B12 and B6 cofactors.
What is the difference between food sources of folate and supplemental 5-MTHF?
Dietary folate must be reduced, methylated, and converted through multiple enzymatic steps to become 5-MTHF, which depends on adequate MTHFR enzyme function and various cofactors; supplemental 5-MTHF is already in the active form and bypasses these conversion steps. Individuals with MTHFR variants or compromised folate metabolism may absorb and utilize dietary folate inefficiently, whereas 5-MTHF supplementation provides direct bioavailable folate cofactor regardless of enzyme capacity. Food sources like leafy greens and legumes provide folate, but supplemental 5-MTHF ensures tissue repletion more reliably in those with metabolic constraints.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w 5-methyltetrahydrofolate-5-mthf curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
